MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Clinical trials for MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS explained in plain language.
Never miss a new study
Get alerted when new MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS trials appear
Sign up with your email to follow new studies for MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug D-2570 aims to quiet Flare-Ups in ulcerative colitis
Disease control OngoingThis study tests whether an experimental drug called D-2570 can help people with moderately to severely active ulcerative colitis achieve remission. About 120 adults will receive either D-2570 or a placebo daily for 12 weeks. The main goal is to see if more people on D-2570 reach…
Matched conditions: MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Phase: PHASE2 • Sponsor: InventisBio Co., Ltd • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New hope for ulcerative colitis: phase 3 trial of afimkibart underway
Disease control OngoingThis Phase 3 trial tests whether the drug Afimkibart can help people with moderate-to-severe ulcerative colitis achieve remission. About 400 adults who have not responded well to other treatments will receive either Afimkibart or a placebo. The study measures remission at 12 and …
Matched conditions: MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for chinese ulcerative colitis patients: vedolizumab trial shows promise
Disease control OngoingThis study tests whether vedolizumab, given as an IV infusion, can help Chinese adults with moderate to severe ulcerative colitis. About 392 participants will receive either the drug or a placebo. The goal is to see if it reduces symptoms like diarrhea and bleeding, and helps ach…
Matched conditions: MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC